Bank of New York Mellon Corp cut its position in shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.6% during the first quarter, Holdings Channel reports. The fund owned 56,657 shares of the specialty pharmaceutical company’s stock after selling 6,696 shares during the period. Bank of New York Mellon Corp’s holdings in Agile Therapeutics were worth $182,000 at the end of the most recent reporting period.

Separately, Renaissance Technologies LLC boosted its stake in shares of Agile Therapeutics by 209.2% in the fourth quarter. Renaissance Technologies LLC now owns 64,000 shares of the specialty pharmaceutical company’s stock worth $365,000 after buying an additional 43,300 shares in the last quarter. 79.89% of the stock is owned by institutional investors.

Shares of Agile Therapeutics, Inc. (NASDAQ AGRX) traded down 0.61% during midday trading on Friday, hitting $3.25. 19,247 shares of the company were exchanged. Agile Therapeutics, Inc. has a one year low of $1.82 and a one year high of $8.15. The firm’s market cap is $93.62 million. The company’s 50 day moving average price is $4.09 and its 200 day moving average price is $3.25.

Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings data on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. During the same period last year, the business posted ($0.29) earnings per share. Equities analysts expect that Agile Therapeutics, Inc. will post ($1.05) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/11/bank-of-new-york-mellon-corp-sells-6696-shares-of-agile-therapeutics-inc-agrx.html.

A number of equities research analysts recently weighed in on the stock. Noble Financial restated a “buy” rating on shares of Agile Therapeutics in a research note on Sunday, July 30th. HC Wainwright assumed coverage on shares of Agile Therapeutics in a research note on Wednesday, July 19th. They set a “buy” rating and a $10.00 price objective on the stock. ValuEngine cut shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Royal Bank Of Canada set a $8.00 price objective on shares of Agile Therapeutics and gave the company a “buy” rating in a research note on Sunday, July 16th. Finally, Janney Montgomery Scott restated a “buy” rating and set a $15.00 price objective on shares of Agile Therapeutics in a research note on Friday, July 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Agile Therapeutics has an average rating of “Buy” and a consensus target price of $9.08.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Want to see what other hedge funds are holding AGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agile Therapeutics, Inc. (NASDAQ:AGRX).

Institutional Ownership by Quarter for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Stock Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related stocks with our FREE daily email newsletter.